59
Participants
Start Date
October 25, 2016
Primary Completion Date
November 19, 2024
Study Completion Date
February 28, 2026
nab-Paclitaxel
nab-Paclitaxel: 125 mg/m\^2 intravenously (IV)
Gemcitabine
Gemcitabine: 1000 mg/m\^2 intravenously (IV)
A.I. duPont Hospital for Children, Delaware - Nemours, Wilmington
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
University of North Carolina at Chapel Hill, Chapel Hill
Carolinas Medical Center, Levine Cancer Institute, Charlotte
Nemours Children's Clinic, Jacksonville
Shand's Hospital for Children at the University of Florida, Gainesville
Holtz Children's Hospital at the University of Miami, Miami
H. Lee Moffitt Cancer Center and Research Institute, Coordinating Center, Tampa
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham
Vanderbilt - Ingram Cancer Center, Nashville
University of Kentucky, Lexington
Nationwide Children's Hospital, Columbus
Children's Hospital Los Angeles, Los Angeles
Connecticut Children's Medical Center, Hartford
National Pediatric Cancer Foundation
OTHER
H. Lee Moffitt Cancer Center and Research Institute
OTHER